Tornier Names David H. Mowry President and Chief Executive Officer

  Tornier Names David H. Mowry President and Chief Executive Officer

Business Wire

AMSTERDAM -- February 21, 2013

Tornier, N.V. (NASDAQ: TRNX), a global medical device company focused on
providing surgical solutions to orthopaedic extremity specialists, announced
today that its Board of Directors has appointed David H. Mowry as President
and Chief Executive Officer, effective immediately.

Sean D. Carney, Chairman of Tornier, commented, “Dave has demonstrated an
intensity and concentration in executing on the key initiatives in his charge
since joining Tornier in July 2011 as Chief Operating Officer. That expertise,
combined with his extensive industry experience and outstanding leadership
qualities, make Dave the right executive to continue to build Tornier’s strong
brand and reputation in the extremities market.”

David H. Mowry commented, “Tornier’s industry expertise, broad product
portfolio, and cadence of delivering innovation position the Company as a
recognized global leader in the large and growing extremities markets. We
believe the increased focus on execution of our US sales channel alignment,
OrthoHelix integration, and delivering through our strong product pipeline
will return Tornier to double-digit, constant currency revenue growth on a pro
forma basis. I am grateful to the Board of Directors for the opportunity to
lead Tornier, and I am excited to work with the talented and dedicated Tornier

Mr. Mowry joined Tornier N.V. in July 2011 as Chief Operating Officer. He
brings to Tornier 23 years of medical device industry experience in various
engineering and management assignments. Prior to Tornier, Mr. Mowry served as
Senior Vice President and President of the Neurovascular Division of Covidien
plc, and in the same position with ev3 Inc., prior to its acquisition by
Covidien. Before joining ev3, Mr. Mowry served as Vice President of Operations
and Logistics at the Zimmer Spine division of Zimmer Holdings Inc. Mr. Mowry
is a graduate of the United States Military Academy at West Point, New York
with a degree in Engineering and Mathematics.

About Tornier

Tornier is a global medical device company focused on serving extremities
specialists who treat orthopaedic conditions of the shoulder, elbow, wrist,
hand, ankle and foot. The Company’s broad offering of over 100 product lines
includes joint replacement, trauma, sports medicine, and ortho-biologic
products through Tornier and OrthoHelix brands to treat the extremities, as
well as joint replacement products for the hip and knee in certain
international markets. Since its founding approximately 70 years ago,
Tornier’s “Specialists Serving Specialists” philosophy has fostered a
tradition of innovation, intense focus on surgeon education, and commitment to
advancement of orthopaedic technology stemming from its close collaboration
with orthopaedic surgeons and thought leaders throughout the world. For more
information regarding Tornier, visit, or OrthoHelix, visit

Forward-Looking Statements

Statements contained in this release that relate to future, not past, events
are forward-looking statements under the Private Securities Litigation Reform
Act of 1995. Forward-looking statements are based on current expectations of
future events and often can be identified by words such as “believe,” expect,”
“should,” “project,” “anticipate,” “intend,” “will,” “may,” “could,” “would,”
“continue,” “future,” other words of similar meaning or the use of future
dates. Examples of forward-looking statements in this release include
Tornier’s return to double-digit constant currency revenue growth.
Forward-looking statements by their nature address matters that are, to
different degrees, uncertain. Uncertainties and risks may cause Tornier’s
actual results to be materially different than those expressed in or implied
by Tornier’s forward-looking statements. For Tornier, such uncertainties and
risks include, among others, Tornier’s future operating results and financial
performance, fluctuations in foreign currency exchange rates, the effect of
global economic conditions, the European sovereign debt crisis, and austerity
measures, risks associated with Tornier’s international operations and
expansion, risks associated with Tornier’s recent acquisition of OrthoHelix
and the new credit facility agreement, the timing of regulatory approvals and
introduction of new products, physician acceptance, endorsement, and use of
new products; the effect of regulatory actions, changes in and adoption of
reimbursement rates, potential product recalls, competitor activities, the
effect of changes in Tornier’s distribution channels and the costs and effects
of litigation and changes in tax and other legislation. More detailed
information on these and other factors that could affect Tornier’s actual
results are described in Tornier’s filings with the U.S. Securities and
Exchange Commission, including its most recent annual report on Form 10-K and
subsequent quarterly reports on Form 10-Q. Tornier undertakes no obligation to
update its forward-looking statements.


Tornier N.V.
Shawn McCormick
Chief Financial Officer
(952) 426-7646
Press spacebar to pause and continue. Press esc to stop.